Launched(USA) Infection: NCE Approved NDA approved Global Trius Therapeutics(USA) ABSSSI (EU) Pneumonia: NCE PhⅢ(Global) Global Trius Therapeutics(USA) HA/VAP Erectile Dysfunction, Benign NCE PhⅡ Japan Meiji Seika Pharma Prostatic Hyperplasia etc. China, Luye Pharma Group(China), Type2 NDA NCE Ready to IND India, Alkem Laboratories(India), Eurofarma diabetes submitted Brazil Laboratories(Brazil) Producst Dosage Active Ingredient Indication International Certification Name form Atorvastatin Atorvastatin API Hyperlipidemia treatment PMDA DMF Cycloserine Cycloserine API Tuberculosis treatment WHO DMF Epirubicin Epirubicin API Anti cancer agent CEP Monotaxel Docetaxel Injection Anti cancer agent Europe approval
NCE Infection: ABSSSI Approved Launched(USA) NDA approved (EU) Global Trius Therapeutics(USA) NCE Pneumonia: HA/VAP PhⅢ(Global) Global Trius Therapeutics(USA) NCE Erectile Dysfunction, Benign Prostatic Hyperplasia etc. PhⅡ Japan Meiji Seika Pharma NCE Type2 diabetes NDA submitted Ready to IND China, India, Brazil Luye Pharma Group(China), Alkem Laboratories(India), Eurofarma Laboratories(Brazil) Producst Name Active Ingredient Dosage form Indication International Certification Atorvastatin Atorvastatin API Hyperlipidemia treatment PMDA DMF Cycloserine Cycloserine API Tuberculosis treatment WHO DMF Epirubicin Epirubicin API Anti cancer agent CEP Monotaxel Docetaxel Injection Anti cancer agent Europe approval